Compare Stocks → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYADNASDAQ:EVLONASDAQ:KTOVNASDAQ:NERVNASDAQ:OBSV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYADCelyad Oncology$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsEVLOEvelo Biosciences$0.05-2.1%$0.05$0.03▼$13.93$884K1.9439,867 shs37,715 shsKTOVPurple Biotech$0.53-0.9%$4.16$2.20▼$14.40$8.26M2.371.18 million shs104,786 shsNERVMinerva Neurosciences$2.54+8.5%$2.57$2.29▼$13.49$17.76M0.2793,146 shs22,140 shsOBSVObsEva$0.00-60.0%$0.01$0.08▼$2.14$156K0.688.94 million shs756 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYADCelyad Oncology0.00%0.00%0.00%0.00%-3.07%EVLOEvelo Biosciences+9.43%+13.60%+19.00%-4.80%-98.27%KTOVPurple Biotech-0.86%+3.00%-24.94%-31.04%-73.60%NERVMinerva Neurosciences-1.27%-2.90%-7.87%-81.23%-61.00%OBSVObsEva0.00%0.00%-28.57%-91.67%-94.05%Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYADCelyad OncologyN/AN/AN/AN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AN/AN/AN/AN/ANERVMinerva Neurosciences3.9177 of 5 stars3.05.00.04.63.10.00.0OBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYADCelyad OncologyN/AN/AN/AN/AEVLOEvelo Biosciences2.00HoldN/AN/AKTOVPurple BiotechN/AN/AN/AN/ANERVMinerva Neurosciences2.00Hold$7.00175.59% UpsideOBSVObsEvaN/AN/AN/AN/ACurrent Analyst RatingsLatest OBSV, EVLO, NERV, CYAD, and KTOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2024NERVMinerva NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$11.00 ➝ $7.002/27/2024NERVMinerva NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$11.00(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYADCelyad Oncology$110K144.65N/AN/A$0.20 per share3.00EVLOEvelo BiosciencesN/AN/AN/AN/A($0.92) per shareN/AKTOVPurple Biotech$1M8.26N/AN/A$5.56 per share0.09NERVMinerva NeurosciencesN/AN/AN/AN/A($4.07) per shareN/AOBSVObsEva$20.11M0.01N/AN/A$0.41 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYADCelyad Oncology-$9.14MN/A0.00∞N/AN/AN/AN/AN/AEVLOEvelo Biosciences-$114.53M-$13.29N/A∞N/AN/AN/A-189.58%5/13/2024 (Estimated)KTOVPurple Biotech-$5.85M-$3.00N/AN/AN/AN/AN/AN/AN/ANERVMinerva Neurosciences-$30M-$4.47N/AN/AN/AN/AN/A-53.19%8/6/2024 (Estimated)OBSVObsEva-$58.38M-$0.92N/A∞N/AN/A-416.36%-92.01%N/ALatest OBSV, EVLO, NERV, CYAD, and KTOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2024Q1 2024NERVMinerva Neurosciences-$1.20-$1.13+$0.07-$1.13N/AN/A2/22/2024Q4 2023NERVMinerva Neurosciences-$0.88-$1.19-$0.31-$1.19N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYADCelyad OncologyN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYADCelyad OncologyN/AN/AN/AEVLOEvelo BiosciencesN/A0.480.48KTOVPurple BiotechN/A2.22N/ANERVMinerva NeurosciencesN/A12.5812.58OBSVObsEvaN/A0.610.61OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYADCelyad OncologyN/AEVLOEvelo Biosciences0.31%KTOVPurple Biotech30.72%NERVMinerva Neurosciences34.56%OBSVObsEva17.52%Insider OwnershipCompanyInsider OwnershipCYADCelyad Oncology0.94%EVLOEvelo Biosciences1.02%KTOVPurple Biotech2.98%NERVMinerva Neurosciences6.40%OBSVObsEva14.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYADCelyad Oncology9526.52 million26.28 millionNot OptionableEVLOEvelo Biosciences6618.98 million18.79 millionNo DataKTOVPurple Biotech915.73 millionN/ANot OptionableNERVMinerva Neurosciences96.99 million6.55 millionNot OptionableOBSVObsEva4877.97 million66.74 millionNot OptionableOBSV, EVLO, NERV, CYAD, and KTOV HeadlinesSourceHeadlineObsEva (NASDAQ:OBSV) Coverage Initiated at StockNews.comamericanbankingnews.com - May 6 at 2:44 AMObsEva (NASDAQ:OBSV) Coverage Initiated by Analysts at StockNews.comamericanbankingnews.com - April 28 at 2:20 AMObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listinglobenewswire.com - April 3 at 1:00 AMObsEva Announces Update on Board of Directorsglobenewswire.com - March 19 at 2:00 AMObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023globenewswire.com - February 28 at 1:00 AMObsEva Stock (OTC:OBSEF) Dividends: History, Yield and Datesbenzinga.com - February 26 at 12:34 AMObsEva SA OBSNmorningstar.com - November 11 at 10:37 PMObsEva SA OBSEFmorningstar.com - November 11 at 7:36 AMObsEva (NASDAQ: OBSV)fool.com - June 18 at 11:34 PMTocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObservernews.google.com - May 10 at 1:37 AMObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo Financenews.google.com - May 2 at 1:32 PMObsEva Says Fabien De Ladonchamps Is New CEO - Nasdaqnews.google.com - May 2 at 8:31 AMObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswirenews.google.com - May 2 at 1:20 AMGameto Appoints Teri Loxam as Chief Financial Officer - citybiznews.google.com - April 28 at 11:20 PMObsEva Annual Report 2022 - Marketscreener.comnews.google.com - April 28 at 6:20 PMObsEva Annual Report 2022 - Yahoo Financenews.google.com - April 28 at 6:20 PMObsEva Annual Report 2022 - Benzinganews.google.com - April 28 at 1:20 PMObsEva Annual Report 2022 - EIN Newsnews.google.com - April 28 at 1:20 PMGameto Expands Executive Team with the Addition of Teri Loxam as ... - PR Newswirenews.google.com - April 28 at 8:19 AMEndometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital Journalnews.google.com - April 26 at 6:27 PMEndometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages - openPRnews.google.com - April 23 at 8:45 PMObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq - Marketscreener.comnews.google.com - April 21 at 3:44 PMObsEva Announces Change of Central Securities Depositary - Yahoo Financenews.google.com - April 20 at 11:41 PMObsEva Announces Change of Central Securities Depositary - GlobeNewswirenews.google.com - April 20 at 1:10 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCelyad OncologyNASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Evelo BiosciencesNASDAQ:EVLOEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Purple BiotechNASDAQ:KTOVPurple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.Minerva NeurosciencesNASDAQ:NERVMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.ObsEvaNASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.